Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Medtide, Inc. Class H ( (HK:3880) ) is now available.
Medtide Inc. expects its 2025 revenue to rise to about RMB555 million to RMB585 million, up roughly 25% to 32% year on year, while profit is projected to surge to RMB200 million to RMB230 million, an increase of about 238% to 289% driven by strong peptide service demand and operational efficiencies. The company also anticipates higher adjusted net profit and attributes the earnings momentum to its “going with compound” strategy, cost savings and a fair value gain as redemption liabilities were converted into equity upon its H-share listing, although it cautions that the figures are preliminary and unaudited.
The most recent analyst rating on (HK:3880) stock is a Hold with a HK$38.00 price target. To see the full list of analyst forecasts on Medtide, Inc. Class H stock, see the HK:3880 Stock Forecast page.
More about Medtide, Inc. Class H
Medtide Inc. is a People’s Republic of China–incorporated joint stock company listed in Hong Kong that operates an integrated contract research, development and manufacturing organization platform. The group focuses on peptide-related services, including projects in the rapidly expanding global glucagon like peptide-1 market, and emphasizes fast project delivery and strong execution for key biopharmaceutical customers.
Average Trading Volume: 138,203
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$3.75B
For detailed information about 3880 stock, go to TipRanks’ Stock Analysis page.